Nephroangiosclerotic chronic kidney disease's primary and secondary prevention is actually based on blood pressure control and reduction of proteinuria. In proteinuric patients, blood pressure control has to be obtained by blocking renin–angiotensin axis, even in patients with moderate to severe chronic kidney disease. Combination therapy with angiotensin converting enzyme inhibitor (ACEi) drugs and angiotensin II receptor blockers (ARB) doesn't imply addictive protective effects. It could be tested in selected patients with proteinuria levels above 1 g/day. Combination therapy with ACEi and anti–aldosteronic agents seems to be promising but we need more multicentric trials.
ManciaG., De BackerG., DominiczakA., CifkovaR.2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens2007; 25(9): 1751–62.
2.
GoA.S., ChertowG.M., FanD., McCullochC.E., HsuC.Y.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New Engl J Med2004; 351: 1296–305.
3.
SarnakM.J., GreeneT., WangX., BeckG., KusekJ.W., CollinsA.J., LeveyA.S.The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med2005; 142(5): 342–51.
4.
ImaiE., YamagataK., IsekiK., IsoH., HorioM., MkinoH., HishidaA., MatsuoS.Kidney disease screening program in Japan: history, outcome, and perspectives. Clin J Am Soc Nephrol2007; 2: 1360–6.
5.
KlahrS., LeveyA.S., BeckG.J., CaggiulaA.W., HunsickerL., KusekJ.W., StrikerG.The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med1994; 330: 877–84.
6.
JafarT.H., SchmidC.H., LandaM., GiatrasI.Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med2001; 135: 73–87.
7.
BrennerB.M., CooperM.E., de ZeeuwD., KeaneW.F.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001; 345(12): 861–9.
8.
NakaoN., YoshimuraA., MoritaH., TakadaM., KayanoT., IdeuraT.Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomised controlled trial. Lancet2003; 361: 117–224.
9.
BianchiS., BigazziR., CampeseV.M.Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int2006; 70: 2116–23.
10.
HouF.F., ZhangX., ZhangG.H., XieD.Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med2006; 354: 131–140.
